The data from this study support the widely held belief that insulin secretion decreases over time in patients with type 2 diabetes mellitus. They also indicate, however, that the rate of decline of insulin secretion, as assessed by fasting and postglucagon C-peptide concentrations, can be variable within a specific individual and that decline does not occur in all patients; thus, the predictive value of any single measurement is limited. Collectively, these data indicate that even though a decrease in insulin secretion over time is characteristic of type 2 diabetes mellitus, it is not inevitable. Therefore, the effectiveness of therapies designed to preserve or increase beta cell function varies from one patient to another.
We thank Dr. George Klee for performing the C-peptide measurements, Janice Cabellon for providing technical support, and Monica Davis for assisting with preparation of the submitted manuscript.Funding information
This study was supported in part by the US Public Health Service (DK-29953, NS-36797, and DK-26910) Natural History of Insulin Secretion, Endocr Pract. 2006;12(No. 4) 393 and by the Mayo Foundation.
A1C = hemoglobin A1c; UKPDS = United Kingdom Prospective Diabetes Study
Dr. Robert A. Rizza, Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic Rochester, 200 1st Street Southwest, Room 5-194 Joseph, Rochester, MN 55905. © 2006 AACE.
Endocr Pract. 2006;12(4):388-393. © 2006 American Association of Clinical Endocrinologists
Cite this: Effects of Duration of Type 2 Diabetes Mellitus on Insulin Secretion - Medscape - Jul 01, 2006.